Moleculin Biotech, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where shareholders approved two key proposals: granting the Board of Directors authority to enact a reverse stock split and increasing the number of shares authorized under its 2024 Equity Plan.
Key Details
- Reverse Stock Split Authorization: The Board now has the authority to effect a reverse stock split of the company's common stock at a ratio between 1-for-2 and 1-for-20. The Board can decide whether to implement the split at any time prior to the one-year anniversary of the annual meeting.
- Equity Plan Expansion: Stockholders approved an amendment to the 2024 Equity Plan, increasing the number of shares authorized for issuance by 3,861,894. The total number of shares available under the plan is now 3,875,999.
- Other Meeting Outcomes: All five director nominees were elected, and the appointment of Grant Thornton, LLP as the independent registered public accountant was ratified. A proposal to eliminate supermajority voting requirements did not receive sufficient votes for approval.